| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10689-016-9873-9 |
| P698 | PubMed publication ID | 26833043 |
| P50 | author | Francois Eisinger | Q53791638 |
| Patrice Viens | Q57015162 | ||
| Renaud Sabatier | Q82068977 | ||
| Magali Provansal | Q112902541 | ||
| P2093 | author name string | Hagay Sobol | |
| Cornel Popovici | |||
| Eric Lambaudie | |||
| Emmanuelle Charaffe-Jauffret | |||
| Tetsuro Noguchi | |||
| Laetitia Rabayrol | |||
| Jessica Moretta | |||
| Doriane Livon | |||
| Elisabeth Cherau | |||
| Elise Lavit | |||
| P2860 | cites work | Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 |
| BRCAness: finding the Achilles heel in ovarian cancer | Q24630872 | ||
| Meta-analysis of BRCA1 and BRCA2 penetrance | Q24654786 | ||
| TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival | Q24812743 | ||
| Effect of Screening on Ovarian Cancer Mortality | Q26253810 | ||
| Clinical epidemiology of epithelial ovarian cancer in the UK | Q26822648 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer | Q27851709 | ||
| Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas | Q27852671 | ||
| Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study | Q27853070 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration | Q28222847 | ||
| Hallmarks of 'BRCAness' in sporadic cancers | Q29618825 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis | Q33553318 | ||
| Integrated analysis of germline and somatic variants in ovarian cancer. | Q33630954 | ||
| Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. | Q34049228 | ||
| Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer | Q34049234 | ||
| Breast-cancer risk in families with mutations in PALB2 | Q34148873 | ||
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. | Q34422265 | ||
| Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis | Q34860429 | ||
| A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO | Q35445946 | ||
| Improved survival in BRCA2 carriers with ovarian cancer | Q35828679 | ||
| Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. | Q35848153 | ||
| Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival | Q35914568 | ||
| BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group | Q36145443 | ||
| Mutation screening of RAD51C in high-risk breast and ovarian cancer families | Q36162179 | ||
| Hereditary ovarian cancer. | Q36235943 | ||
| 'BRCAness' and its implications for platinum action in gynecologic cancer | Q36380704 | ||
| Are there candidates for high-dose chemotherapy in ovarian carcinoma? | Q36468856 | ||
| Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer | Q36763684 | ||
| Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study | Q36912591 | ||
| Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway | Q37203864 | ||
| Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. | Q37263790 | ||
| Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis | Q38119029 | ||
| Ovarian cancer: risk factors, treatment and management | Q38143316 | ||
| PARP inhibitors in ovarian cancer: current status and future promise | Q38194324 | ||
| Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden | Q38503154 | ||
| Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. | Q39816174 | ||
| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 | ||
| BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer | Q42477044 | ||
| Failure of BRCA1 dysfunction to alter ovarian cancer survival. | Q44044626 | ||
| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer | Q44461877 | ||
| Preoperative genetic testing affects surgical decision making in breast cancer patients | Q44683977 | ||
| Survival analysis in familial ovarian cancer, a case control study | Q45280874 | ||
| The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience. | Q45391582 | ||
| Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience | Q45822470 | ||
| BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study | Q46119283 | ||
| Improved survival in women with BRCA-associated ovarian carcinoma | Q46693199 | ||
| Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients | Q46799385 | ||
| Analysis of PALB2 in a cohort of Italian breast cancer patients: identification of a novel PALB2 truncating mutation. | Q50961264 | ||
| Response-guided neoadjuvant chemotherapy for breast cancer. | Q52882601 | ||
| Predictability of the survival of patients with advanced ovarian cancer. | Q53409532 | ||
| Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. | Q53668957 | ||
| Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors | Q57250723 | ||
| Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility | Q57305903 | ||
| BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes | Q57309394 | ||
| “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations | Q57694467 | ||
| Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program | Q57903119 | ||
| Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations | Q59689022 | ||
| BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer | Q62112707 | ||
| Clinicopathologic features of BRCA-linked and sporadic ovarian cancer | Q73782102 | ||
| Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1 | Q74361088 | ||
| Inactivation of BRCA1 and BRCA2 in ovarian cancer | Q74801177 | ||
| Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer | Q80423982 | ||
| Overall survival in BRCA-associated ovarian cancer: case-control study of an Italian series | Q83407749 | ||
| [Hereditary forms of ovarian cancer] | Q83505157 | ||
| Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease | Q84534751 | ||
| BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer | Q85363448 | ||
| P433 | issue | 4 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 497-506 | |
| P577 | publication date | 2016-10-01 | |
| P1433 | published in | Familial Cancer | Q15761917 |
| P1476 | title | Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis | |
| P478 | volume | 15 |
| Q55377222 | Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. |
| Q90966998 | BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer |
| Q37702214 | Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis |
Search more.